- Dhanuka Agritech is fundamentally a crop-protection company - it makes the chemicals that stop insects, weeds and fungi from destroying harvests, reaching more than 10 million farmers across India. It was born in 1980 when Chairman R.G. Agarwal took over a sick pesticide unit and rebuilt it into a branded-formulations house, a turnaround that set the pattern for everything that followed. The recurring approach is to bring novel, globally proven molecules into India through deep partnerships with Japanese, European and American innovators, then push them through a distribution engine that treats crop-protection chemicals like a rural fast-moving consumer good.
Business segments
A single engine - branded crop-protection formulations - built on a foundation of exclusive global innovation partnerships, in-house manufacturing and a pan-India distribution network that reaches the village retailer.
1. Branded crop-protection formulations: the company's sole business engine
Dhanuka makes and sells roughly 90 branded products across insecticides, herbicides, fungicides and biologicals, delivered through 6,500 distributors and over 80,000 retailers to farmers in every major Indian state.
- A portfolio built for the field, not the lab - the company markets around 90 products spanning insecticides (41% of revenue in FY26), herbicides (31%), fungicides (14%) and a biologicals-and-others category (14%), with more than 300 registrations backing the range. Products come in liquids, powders and granules, in pack sizes from 2 grams to 20 litres - small enough for a farmer with a single acre.
- Distributed like a rural FMCG - the company describes its model as a "Rural FMCG Play", pushing product through roughly 6,500 distributors and more than 80,000 retailers to reach over 10 million farmers. Sales to dealers account for about 88% of total sales, and the top 10 dealers represent less than 3% of that - no single customer holds the company hostage.
- A field army that teaches, not just sells - more than 1,000 techno-commercial staff and a force of qualified agri-graduates called "Dhanuka Doctors" run village-level demonstrations on soil health, irrigation and seed treatment, while the company conducted over 115,000 awareness programs in FY26 alone. The "Har Beej ko Suraksha Ka Teeka" seed-treatment campaign was adopted by the Government of India.
- Quality and service as the generic defence - when generic competitors erode prices, the company upgrades products to new formulations or variants, and its channel partners stick with Dhanuka's generics because of the quality and service wrapped around them. In FY22, it voluntarily dropped all Red Triangle (highly toxic) products from its basket, taking a roughly Rs 20 crore revenue hit to reposition the portfolio.
- Four plants and 41 warehouses - manufacturing happens at Sanand, Keshwana, Udhampur and the newer Dahej facility, with 41 warehouses across the country ensuring stock reaches distributors on demand rather than through large channel placements.
2. 9(3) specialty molecules and global innovation partnerships: the moat inside the engine
Roughly half of Dhanuka's revenue comes from exclusive or first-to-market molecules sourced through alliances with ten multinational innovators - chemistry that generic competitors cannot easily copy.
- Exclusive rights, not just distribution deals - the company partners with ten leading agrochemical innovators from Japan, Europe and the United States, and these alliances contribute approximately 50% of revenue. The key mechanism is the Section 9(3) registration under Indian law, which grants a period of exclusive marketing rights for new molecules - a six-to-seven-year gestation from pipeline to commercial launch.
- Japanese chemistry at the core - collaborations with Nissan Chemical, Hokko Chemical, Mitsui Chemicals and Nippon Soda have produced products like LaNevo (a broad-spectrum insecticide targeting a roughly Rs 1,050 crore addressable market), Purge (a soybean and groundnut herbicide with a roughly Rs 700 crore addressable market) and Dinkar (a paddy herbicide for resistant weeds). The company celebrated 25 years of its Japanese partnerships in FY23.
- Better margins on new launches - new 9(3) products normally carry margins above the company average, and the company targets at least a double-digit market share in the segments where it launches them, with peak revenue expected after three to five years. New molecules as a share of total revenue rose from about 11% in FY21 to nearly 14% in FY26.
- A pipeline measured in years - during FY26 the company secured two new 9(3) registrations (Ipflufenoquin for rice and Sulfoxaflor for cotton) and nine generic 9(4) registrations, while earlier plans called for eight new 9(3) products in two years. The long development cycle means the challenge is taking the message to millions of farmers spread across India, not finding the chemistry.
3. Biological products: the complementary green portfolio
Dhanuka has built a biologicals division that sells bio-pesticides, bio-fertilizers and bio-stimulants - still small, but designed to sit alongside chemical products in an integrated crop-management offer.
- Nature-derived, in-house developed - the BiologiQ range includes six products (Whiteaxe, Nemataxe, Downil, Sporenil, Myconxt and Omninxt) that can be used alone or combined with conventional chemicals under an Integrated Pest and Nutrition Management plan. The star product, MYCORe Super, is an in-house development from the Dhanuka Agricultural Research Center - a mycorrhizal fungi product targeting a roughly Rs 470 crore addressable market.
- A small segment with government tailwinds - bio-pesticides account for about 15% of the total pesticides market, and the company expects biologicals to act as a complement to agrochemicals rather than a replacement, with growth supported by government policy. The division was established in FY22, making it the youngest part of the portfolio.
4. International business and the Bayer acquisition: the export seed
Dhanuka's international business is at an infant stage, but the acquisition of global rights to two Bayer active ingredients - Iprovalicarb and Triadimenol - gives it a ready-made export platform across more than 20 countries.
- Bought, not just built - in November 2024, Dhanuka paid roughly Rs 167 crore to acquire the crop-protection active ingredients Iprovalicarb and Triadimenol from Bayer AG, along with the Melody trademark and associated registrations and intellectual property. The acquired portfolio had global revenue of roughly Rs 224 crore in 2023.
- Manufacturing is shifting to India - Dhanuka plans to move production of both formulation and active ingredient to its own facilities, with Iprovalicarb technical manufacturing in India targeted for FY27 and Triadimenol formulation already shifting in FY26. That is how the Dahej chemical-synthesis plant earns its keep beyond domestic supply.
- Exports are still tiny - exports contribute just over 1% of total turnover, serving Bangladesh, Nepal, the UAE and Argentina, but the company has secured export registrations for technicals including Bifenthrin, Thiacloprid and Cyantraniliprole, and is appointing national distributors in markets where it owns the registrations. The Board has approved incorporating subsidiaries in Brazil and Europe to hold brand registrations.
Manufacturing and R&D backbone
Four plants, two R&D centres and a backward-integration bet at Dahej give Dhanuka control over formulation and, increasingly, the technical-grade active ingredients that go into its products.
- Dahej is the backward-integration play - the chemical-synthesis plant at Dahej, Gujarat, on a roughly 137,000-square-metre plot, began trial production of bifenthrin technical in August 2023, moving the company from pure formulation into making its own technical-grade pesticides. The original logic was to improve raw-material procurement through barter and open export avenues.
- Two R&D centres, two jobs - the Dhanuka Agritech Research and Technology Centre (DART) at Palwal, Haryana, houses labs for formulation development, biologicals, soil analysis and bioassays, plus a farmer training centre and research farm for lab-to-land validation. A second chemical R&D lab at Sanand, Gujarat, with 30 chemists and 15 fume hoods, focuses on process technology for generic and late-stage patented products, feeding the Dahej plant.
- A patent track record - the company holds a patent for a water-soluble granular insecticidal composition (Cartap Hydrochloride 75% SG) and has been granted a patent for a new herbicide combination (Halosulfuron Methyl and Metribuzin) for control of weeds in sugarcane, with product launch expected in 2023. MoUs with ICAR and multiple agricultural universities give it a research network that extends well beyond its own walls.
Group structure and partners
Dhanuka Agritech is a standalone company with no subsidiaries, associates or joint ventures - its partnerships are contractual alliances with global innovators, not equity ties.
- No subsidiaries as of March 2026 - the company previously had two wholly owned subsidiaries: Dhanuka Chemicals Private Limited (struck off in July 2024) and Dhanuka Agri-solutions Private Limited in Bangladesh (dissolved in August 2023); neither ever commenced operations.
- Ten innovation partners, no equity - the company's ten multinational partners include Nissan Chemical, Hokko Chemical, Mitsui Chemicals, Nippon Soda and FMC Corporation, all structured as commercial alliances rather than joint ventures. The Bayer deal for Iprovalicarb and Triadimenol is an asset acquisition of global rights, not a corporate tie-up.
- Exploring biologicals with Kimitec - a non-binding Letter of Intent signed in January 2024 with Spain's Kimitec Group explores a potential joint venture for developing and commercialising biological products from natural molecules in India, including a possible R&D facility.